ALKERMES reported $7.61B in Market Capitalization this November of 2026, considering the latest stock price and the number of outstanding shares.





Market Capitalization Change Date
AbbVie USD 508.97B 46.71B Nov/2026
Acadia Pharmaceuticals USD 3.57B 100M Nov/2026
ALKERMES USD 7.43B 629M Nov/2026
Amgen USD 247.94B 20.06B Nov/2026
Biogen USD 33.38B 1.48B Sep/2026
BioMarin Pharmaceutical USD 10.68B 936M Nov/2026
Bristol-Myers Squibb USD 127.46B 9.81B Sep/2026
Coherus Biosciences USD 172M 19M Dec/2025
Eli Lilly USD 1.09T 40.33B Sep/2026
Gilead Sciences USD 184.82B 27.96B Sep/2026
Heron Therapeutics USD 238M 7M Dec/2025
Ionis Pharmaceuticals USD 4.24B 3.18B Nov/2026
J&J USD 653.61B 42.25B Sep/2026
Malin Corporation EUR 133.52M 29.05M Aug/2026
Merck USD 375.59B 17.09B Nov/2026
Nektar Therapeutics USD 2.12B 1.26B Mar/2026
Neurocrine Biosciences USD 16.38B 1.96B Nov/2026
Otsuka Holdings JPY 6.08T 213B Sep/2026
Ovoca Bio EUR 1.17M 18.38K Dec/2025
Pfizer USD 165.12B 1.71B Nov/2026
Vertex Pharmaceuticals USD 140.44B 7.93B Nov/2026